1
|
Ku G, Di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, Lonardi S, Wainberg Z, Ajani J, Chao J, Barlaskar F, Kawaguchi Y, Qin A, Singh J, Meinhardt G, Van Cutsem E. 1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1323] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
2
|
Arita J, Kiritani S, Ichida A, Kawaguchi Y, Akamatsu N, Kaneko J, Hasegawa K. 497P Prognostic impact of venous and lymphatic invasion of pancreatic neuroendocrine neoplasm in patients undergoing resection. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Kawaguchi Y, Kita R, Kimura T, Goto R, Takayama T, Izumi N, Kudo M, Kaneko S, Yamanaka N, Inomata M, Shimada M, Baba H, Koike K, Omata M, Makuuchi M, Matsuyama Y, Yamada Y, Kokudo N, Hasegawa K. 723P Medical expenditures and treatment efficacy of patients who had initial hepatocellular carcinoma and underwent surgery or radiofrequency ablation: Accompanying research of the SURF trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
4
|
Nakajima E, Sugita M, Morishita Y, Miyazaki T, Kanzawa H, Kawaguchi Y, Ono S, Hirsch F, Ikeda N, Furukawa K. EP16.03-029 SLIT2 Expression in NSCLC With Long-Term Response to Pemetrexed. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
5
|
Shitara K, Barlaskar F, Franke F, Kawaguchi Y, Shen L, Kamio T, Meinhardt G, Tabernero J. P-159 Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04): A randomized phase 3 study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
6
|
Hirose H, Higuchi T, Takagi K, Tochimoto A, Kawaguchi Y, Harigai M. AB0667 EFFECT OF TEMPERATURE VARIATION ON SERUM KL-6 LEVELS IN PATIENTS WITH SYSTEMIC SCLEROSIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundSerum Krebs von den Lungen-6 (KL-6) levels has much evidence as a biomarker about the progression and prognosis of interstitial lung disease (ILD), including systemic sclerosis (SSc)-associated ILD1-4. However, serum KL-6 levels often fluctuate regardless of the progression of ILD. This sometimes mislead the evaluation of the disease activity, however, the reason for the fluctuation has not been clarified.ObjectivesWe tested the hypothesis that serum KL-6 levels are affected by ambient temperature in patients with SSc.MethodsWe defined the warm season(May–October)as the period when the ambient temperature was above the Tokyo metropolitan average ambient temperature announced by the Japan Meteorological Agency, and the cold season (November–April)as the period when the ambient temperature was below the average. ILD was classified based on chest CT findings. Among SSc patients who had visited our department since May 2018, we selected those who had data of serum KL-6 levels at least 3 times in warm and cold seasons from October 2014 to September 2021, respectively. Patients having malignancy were excluded after confirmation of the onset of malignancy using medical record retrospectively. The difference in serum KL-6 levels between warm and cold seasons was evaluated by Wilcoxon’s rank-sum test.ResultsIn total, 252 patients with SSc were included. Median age was 66.3 years, with median disease duration of 13.5 (8.9–19.2)years, diffuse cutaneous type of 94 (37.3%)patients, and concomitant ILD of 120(47.6%)patients (Table 1). The median follow-up was 6.4 (4.4–6.8)years, with median KL-6 measurement of 24(14–39)times. Serum KL-6 levels were significantly higher in the cold season than that in the warm season, with a greater difference in the group with ILD(536 IU/L vs. 492 IU/L, p = 0.0012 in the group with ILD, 364 IU/L vs. 345 IU/L in the group without ILD, p = 0.0028).Table 1.Patients characteristicsWith ILD (n=120)Without ILD (n=132)P valueFemale, n (%)110 (43.7)128 (52.4)0.1Age, years (IQR)65.8(56.1–73.4)66.4(56.0–72.5)0.77Disease duration, years (IQR)14.0 (9.8-21.0)13.0 (8.7-18.0)0.23Modified Rodnan skin score (IQR)10 (4-15)6 (2-11)0.0017Diffuse SSc, n (%)53 (40.2)27 (20.5)<0.001Pulmonary hypertension, n (%)4 (3.3)3 (2.3)0.71ANA positive, n (%)98 (81.7)112 (84.8)0.50SSc-related autoantibody, n (%)98 (81.7)112 (84.8)0.50Anti-centromere antibody, n (%)17 (14.2)86 (71.7)<0.0001Anti-topoisomeraseⅠ antibody, n (%)63 (52.5)8 (6.1)<0.0001Anti-RNA polymerase Ⅲ antibody, n (%)7 (5.8)11 (8.3)0.62Anti-U1-RNP antibody, n (%)15 (12.5)13 (9.8)0.54KL-6, IU/L (IQR)548 (384–876.8)233 (191.3–302)<0.0001KL-6 measurement, times (IQR)33.5(20-45)18.5(12.3-28)<0.0001Steroid use, n (%)68 (56.7)22 (16.7)<0.0001Cyclophosphamide, n (%)44 (36.7)12 (9.1)<0.0001Other Immunosuppressive agents, n (%)31 (25.8)0.002ConclusionOur results suggest that cold ambient temperature may affect serum KL-6 levels in patients with SSc.References[1]Distler O, et al. Eur Respir J.2020;55:1902026.[2]Kuwana M et al. J Rheumatol 2016;43:1825-31[3]Volkmann et al. Arthritis Rheumatol.2019;71:2059-2067[4]Elhai M et al. Arthritis Rheumatol. 2019;71:972-982.Figure 1.Disclosure of InterestsHikaru Hirose Grant/research support from: Bayer Yakuhin, Ltd, Tomoaki Higuchi: None declared, Kae Takagi: None declared, Akiko Tochimoto: None declared, Yasushi Kawaguchi: None declared, Masayoshi Harigai Speakers bureau: AbbVie Japan, Ayumi, Boehringer Ingelheim Japan, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly Japan, GlaxoSmithKline, Kissei, Pfizer Japan Inc, Takeda, Teijin, Consultant of: AbbVie Japan, Boehringer Ingelheim Japan, Bristol-Myers Squibb, Kissei, Teijin, Grant/research support from: AbbVie Japan, Asahi Kasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Kissei, Mitsubishi Tanabe, Nippon Kayaku, Sekisui Medical, Shionogi, Taisho, Takeda, Teijin
Collapse
|
7
|
Ishikawa Y, Tanaka N, Asano Y, Kodera M, Shirai Y, Akahoshi M, Hasegawa M, Matsushita T, Kazuyoshi S, Motegi S, Yoshifuji H, Yoshizaki A, Kohmoto T, Takagi K, Oka A, Kanda M, Tanaka Y, Ito Y, Nakano K, Kasamatsu H, Utsunomiya A, Sekiguchi A, Niro H, Jinnin M, Makino K, Makino T, Ihn H, Yamamoto M, Suzuki C, Takahashi H, Nishida E, Morita A, Yamamoto T, Fujimoto M, Kondo Y, Goto D, Sumida T, Ayuzawa N, Yanagida H, Horita T, Atsumi T, Endo H, Shima Y, Kumanogoh A, Hirata J, Otomo N, Suetsugu H, Koike Y, Tomizuka K, Yoshino S, Liu X, Ito S, Hikino K, Suzuki A, Momozawa Y, Ikegawa S, Tanaka Y, Ishikawa O, Takehara K, Torii T, Sato S, Okada Y, Mimori T, Matsuda F, Matsuda K, Imoto I, Matsuo K, Kuwana M, Kawaguchi Y, Ohmura K, Terao C. OP0112 THE EVER-LARGEST ASIAN GWAS FOR SYSTEMIC SCLEROSIS AND TRANS-POPULATION META-ANALYSIS IDENTIFIED SEVEN NOVEL LOCI AND A CANDIDATE CAUSAL SNP IN A CIS-REGULATORY ELEMENT OF THE FCGR REGION. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundGenome-wide association studies (GWASs) have identified 29 disease-associated single nucleotide polymorphisms (SNPs) for systemic sclerosis (SSc) in non-human leukocyte antigen (HLA) regions (1-7). While these GWASs have clarified genetic architectures of SSc, study subjects were mainly Caucasians limiting application of the findings to Asians.ObjectivesThe study was conducted to identify novel causal variants for SSc specific to Japanese subjects as well as those shared with European population. We also aimed to clarify mechanistic effects of the variants on pathogenesis of SSc.MethodsA total of 114,108 subjects comprising 1,499 cases and 112,609 controls were enrolled in the two-staged study leading to the ever-largest Asian GWAS for SSc. After applying a strict quality control both for genotype and samples, imputation was conducted using the reference panel of the phase 3v5 1,000 genome project data combined with a high-depth whole-genome sequence data of 3,256 Japanese subjects. We conducted logistic regression analyses and also combined the Japanese GWAS results with those of Europeans (6) by an inverse-variance fixed-effect model. Polygenicity and enrichment of functional annotations were evaluated by linkage disequilibrium score regression (LDSC), Haploreg and IMPACT programs. We also constructed polygenic risk score (PRS) to predict SSc development.ResultsWe identified three (FCRLA-FCGR, TNFAIP3, PLD4) and four (EOMES, ESR1, SLC12A5, TPI1P2) novel loci in Japanese GWAS and a trans-population meta-analysis, respectively. One of Japanese novel risk SNPs, rs6697139, located within FCGR gene clusters had a strong effect size (OR 2.05, P=4.9×10-11). We also found the complete LD variant, rs10917688, was positioned in cis-regulatory element and binding motif for an immunomodulatory transcription factor IRF8 in B cells, another genome-wide significant locus in our trans-ethnic meta-analysis and the previous European GWAS. Notably, the association of risk allele of rs10917688 was significant only in the presence of the risk allele of the IRF8. Intriguingly, rs10917688 was annotated as one enhancer-related histone marks, H3K4me1, in B cells, implying that FCGR gene(s) in B cells may play an important role in the pathogenesis of SSc. Furhtermore, significant heritability enrichment of active histone marks and a transcription factor C-Myc were found in B cells both in European and Japanese populations by LDSC and IMPACT, highlighting a possibility of a shared disease mechanism where abnormal B-cell activation may be one of the key drivers for the disease development. Finally, PRS using effects sizes of European GWAS moderately fit in the development of Japanese SSc (AUC 0.593), paving a path to personalized medicine for SSc.ConclusionOur study identified seven novel susceptibility loci in SSc. Downstream analyses highlighted a novel disease mechanism of SSc where an interactive role of FCGR gene(s) and IRF8 may accelerate the disease development and B cells may play a key role on the pathogenesis of SSc.References[1]F. C. Arnett et al. Ann Rheum Dis, 2010.[2]T. R. Radstake et al. Nat Genet, 2010.[3]Y. Allanore et al. PLoS Genet, 2011.[4]O. Gorlova et al. PLoS Genet, 2011.[5]C. Terao et al. Ann Rheum Dis, 2017.[6]E. López-Isac et al. Nat Commun, 2019.[7]W. Pu et al. J Invest Dermatol, 2021.Disclosure of InterestsNone declared
Collapse
|
8
|
Wada T, Mori‐Anai K, Kawaguchi Y, Katsumata H, Tsuda H, Iida M, Arakawa K, Jardine MJ. Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial. J Diabetes Investig 2022; 13:54-64. [PMID: 34212533 PMCID: PMC8756319 DOI: 10.1111/jdi.13624] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 06/23/2021] [Accepted: 06/27/2021] [Indexed: 11/28/2022] Open
Abstract
AIMS/INTRODUCTION The sodium-glucose cotransporter 2 inhibitor, canagliflozin, reduced kidney failure and cardiovascular events in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. We carried out a post-hoc analysis to evaluate the efficacy and safety of canagliflozin in a subgroup of participants in East and South-East Asian (EA) countries who are at high risk of renal complications. MATERIALS AND METHODS Participants with an estimated glomerular filtration rate of 30 to <90 mL/min/1.73 m2 and urinary albumin-to-creatinine ratio of >300-5,000 mg/g were randomized to 100 mg of canagliflozin or a placebo. The effects of canagliflozin treatment on pre-specified efficacy and safety outcomes were examined using Cox proportional hazards regression between participants from EA countries (China, Japan, Malaysia, the Philippines, South Korea and Taiwan) and the remaining participants. RESULTS Of 4,401 participants, 604 (13.7%) were from EA countries; 301 and 303 were assigned to the canagliflozin and placebo groups, respectively. Canagliflozin lowered the risk of primary outcome (composite of end-stage kidney disease, doubling of serum creatinine level, or renal or cardiovascular death) in EA participants (hazard ratio 0.54, 95% confidence interval 0.35-0.84). The effects of canagliflozin on renal and cardiovascular outcomes in EA participants were generally similar to those of the remaining participants. Safety outcomes were similar between the EA and non-EA participants. CONCLUSIONS In the CREDENCE trial, the risk of renal and cardiovascular events was safely reduced in participants from EA countries at high risk of renal events.
Collapse
Affiliation(s)
- Takashi Wada
- Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Graduate School of Medical SciencesKanazawa UniversityKanazawaJapan
| | - Kazumi Mori‐Anai
- Ikuyaku. Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Yutaka Kawaguchi
- Ikuyaku. Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Hideyuki Katsumata
- Ikuyaku. Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationOsakaJapan
| | - Hidetaka Tsuda
- Ikuyaku. Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Mitsutaka Iida
- Ikuyaku. Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Kenji Arakawa
- Ikuyaku. Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Meg J Jardine
- The George Institute for Global Health, UNSWSydneyAustralia
- NHMRC Clinical Trials CenterUniversity of SydneySydneyAustralia
- Concord Repatriation General HospitalSydneyAustralia
| |
Collapse
|
9
|
Kurokawa N, Robinson MK, Bernard C, Kawaguchi Y, Koujin Y, Koen A, Madhi S, Polasek TM, McNeal M, Dargis M, Couture MMJ, Trépanier S, Forrest BD, Tsutsui N. Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. Vaccine 2021; 39:5513-5523. [PMID: 34454786 DOI: 10.1016/j.vaccine.2021.08.052] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 08/06/2021] [Accepted: 08/12/2021] [Indexed: 12/24/2022]
Abstract
BACKGROUND This study is the first clinical trial for a parenteral non-replicating rotavirus vaccine developed using virus-like particle (VLP) technology. METHODS This open-labeled, randomized, placebo-controlled trial was conducted in two parts: Part A (a first-in-human study in Australian adults) and Part B (ascending dose and descending age in South African adults, toddlers and infants). In Part A, two cohorts of 10 adults were assigned to receive a single intramuscular injection of 1 of 2 escalating dose levels of the rotavirus VLP (Ro-VLP) vaccine (7 μg or 21 μg) or placebo. In Part B, one cohort of 10 adults was assigned to receive a single injection of the Ro-VLP vaccine (21 μg) or placebo, two cohorts of 10 toddlers were assigned to receive 2 injections of 1 of 2 escalating dose levels of the Ro-VLP vaccine (7 μg or 21 μg) or placebo 28 days apart, and three cohorts of 20 infants were assigned to receive 3 injections of 1 of 3 escalating dose levels of the Ro-VLP vaccine (2.5 μg, 7 μg or 21 μg) or placebo or 2 doses of oral Rotarix 28 days apart. Safety, reactogenicity and immunogenicity were assessed. RESULTS There were no safety or tolerability concerns after administration of the Ro-VLP vaccine. The Ro-VLP vaccine induced an anti-G1P[8] IgG response in infants 4 weeks after the second and third doses. Neutralizing antibody responses against homologous G1P[8] rotavirus were higher in all Ro-VLP infant groups than in the placebo group 4 weeks after the third dose. No heterotypic immunity was elicited by the Ro-VLP vaccine. CONCLUSIONS The Ro-VLP vaccine was well tolerated and induced a homotypic immune response in infants, suggesting that this technology platform is a favorable approach for a parenteral non-replicating rotavirus vaccine. CLINICAL TRIAL REGISTRATION NCT03507738.
Collapse
Affiliation(s)
- Natsuki Kurokawa
- Mitsubishi Tanabe Pharma Corporation, 17-10, Nihonbashi-Koamicho, Chuo-ku, Tokyo 103-8405, Japan.
| | | | - Catherine Bernard
- International Regulatory Affairs Services, Inc., 10626 Wagon Box Way, Highlands Ranch, CO 80130, USA
| | - Yutaka Kawaguchi
- Mitsubishi Tanabe Pharma Corporation, 17-10, Nihonbashi-Koamicho, Chuo-ku, Tokyo 103-8405, Japan
| | - Yoshito Koujin
- Mitsubishi Tanabe Pharma Corporation, 17-10, Nihonbashi-Koamicho, Chuo-ku, Tokyo 103-8405, Japan
| | - Anthonet Koen
- Respiratory and Meningeal Pathogens Research Unit, Chris Hani Baragwanath Hospital, Berstham Chris Hani Road, Soweto 2013, South Africa
| | - Shabir Madhi
- Respiratory and Meningeal Pathogens Research Unit, Chris Hani Baragwanath Hospital, Berstham Chris Hani Road, Soweto 2013, South Africa
| | - Thomas M Polasek
- Department of Clinical Pharmacology, Royal Adelaide Hospital, Port Road, Adelaide, SA 5000, Australia
| | - Monica McNeal
- Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229-3039, USA
| | - Michèle Dargis
- Medicago Inc., 1020 route de l'Église office 600, Québec, QC, Canada
| | - Manon M-J Couture
- Medicago Inc., 1020 route de l'Église office 600, Québec, QC, Canada
| | - Sonia Trépanier
- Medicago Inc., 1020 route de l'Église office 600, Québec, QC, Canada
| | - Bruce D Forrest
- Cognoscenti Bioscience, LLC., PO Box 444, Nyack, NY 10960, USA
| | - Naohisa Tsutsui
- Mitsubishi Tanabe Pharma Corporation, 17-10, Nihonbashi-Koamicho, Chuo-ku, Tokyo 103-8405, Japan
| |
Collapse
|
10
|
Nangaku M, Kondo K, Kokado Y, Ueta K, Kaneko G, Tandai T, Kawaguchi Y, Komatsu Y. Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD. J Am Soc Nephrol 2021; 32:1779-1790. [PMID: 33883252 PMCID: PMC8425651 DOI: 10.1681/asn.2020091311] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 02/19/2021] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Standard care for treating anemia in patients with CKD includes use of erythropoiesis-stimulating agents, which sometimes involves increased risks of cardiovascular morbidity and mortality. Previous studies in patients with anemia and nondialysis-dependent CKD (NDD-CKD) found significantly elevated hemoglobin levels with use of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, compared with placebo. METHODS In this phase 3, open-label, active-controlled noninferiority trial, we randomized 304 Japanese adults with anemia in NDD-CKD (including erythropoiesis-stimulating agent users and nonusers) to oral vadadustat or subcutaneous darbepoetin alfa for 52 weeks. The primary efficacy end point was average hemoglobin at weeks 20 and 24. Safety data included adverse events (AEs) and serious AEs. RESULTS A total of 151 participants received vadadustat and 153 received darbepoetin alfa. Least squares mean of the average hemoglobin at weeks 20 and 24 was 11.66 (95% confidence interval [95% CI], 11.49 to 11.84) g/dl for vadadustat and 11.93 (95% CI, 11.76 to 12.10) g/dl for darbepoetin alfa. The 95% CIs for both treatments were within the target hemoglobin range (11.0-13.0 g/dl), and the lower 95% confidence limit for the difference between groups (-0.50 g/dl) was above the predefined noninferiority margin (-0.75 g/dl), demonstrating noninferiority of vadadustat to darbepoetin alfa. Similar proportions of patients in each group reported AEs and serious AEs. The most frequent AEs with vadadustat were nasopharyngitis, diarrhea, and constipation. CONCLUSIONS In Japanese patients with NDD-CKD, vadadustat was noninferior to darbepoetin alfa, was effective up to week 52 in terms of average hemoglobin, and was generally well tolerated. These results suggest that vadadustat may be a potential treatment for anemia in this patient population.
Collapse
Affiliation(s)
- Masaomi Nangaku
- Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | | | | | | | - Genki Kaneko
- Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | | | | | - Yasuhiro Komatsu
- Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan
| |
Collapse
|
11
|
Nangaku M, Kondo K, Takabe S, Ueta K, Tandai T, Kawaguchi Y, Komatsu Y. A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents. Ther Apher Dial 2021; 26:45-54. [PMID: 34115437 PMCID: PMC9292398 DOI: 10.1111/1744-9987.13699] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 05/28/2021] [Accepted: 06/10/2021] [Indexed: 12/15/2022]
Abstract
Vadadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor approved in Japan for the treatment of anemia in patients with chronic kidney disease (CKD). This phase 3, open‐label, single‐arm study evaluated the efficacy and safety of vadadustat in 24 Japanese patients with CKD‐associated anemia on hemodialysis who were not receiving erythropoiesis‐stimulating agents (ESAs). Patients received vadadustat for 24 weeks; the starting dose was 300 mg/day and doses were adjusted to achieve the target hemoglobin (Hb) range of 10.0–12.0 g/dL. The least squares mean of average Hb at Weeks 20 and 24 (95% confidence interval) was 10.75 g/dL (10.35, 11.14). The most common adverse event was shunt stenosis (25.0%). Adverse drug reactions (diarrhea and vomiting) occurred in two patients (8.3%) and the severity was mild. Vadadustat increased and maintained Hb levels within the target range and was generally well‐tolerated in Japanese patients with anemia on hemodialysis not receiving ESAs.
Collapse
Affiliation(s)
- Masaomi Nangaku
- Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | | | | | | | | | | | - Yasuhiro Komatsu
- Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan
| |
Collapse
|
12
|
Kawaguchi Y, Kopetz S, Tran Cao HS, Panettieri E, De Bellis M, Nishioka Y, Hwang H, Wang X, Tzeng CWD, Chun YS, Aloia TA, Hasegawa K, Guglielmi A, Giuliante F, Vauthey JN. Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status. Br J Surg 2021; 108:968-975. [PMID: 33829254 DOI: 10.1093/bjs/znab086] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 09/18/2020] [Accepted: 02/11/2021] [Indexed: 12/13/2022]
Abstract
BACKGROUND Most current models for predicting survival after resection of colorectal liver metastasis include largest diameter and number of colorectal liver metastases as dichotomous variables, resulting in underestimation of the extent of risk variation and substantial loss of statistical power. The aim of this study was to develop and validate a new prognostic model for patients undergoing liver resection including largest diameter and number of colorectal liver metastases as continuous variables. METHODS A prognostic model was developed using data from patients who underwent liver resection for colorectal liver metastases at MD Anderson Cancer Center and had RAS mutational data. A Cox proportional hazards model analysis was used to develop a model based on largest colorectal liver metastasis diameter and number of metastases as continuous variables. The model results were shown using contour plots, and validated externally in an international multi-institutional cohort. RESULTS A total of 810 patients met the inclusion criteria. Largest colorectal liver metastasis diameter (hazard ratio (HR) 1.11, 95 per cent confidence interval 1.06 to 1.16; P < 0.001), number of colorectal liver metastases (HR 1.06, 1.03 to 1.09; P < 0.001), and RAS mutation status (HR 1.76, 1.42 to 2.18; P < 0.001) were significantly associated with overall survival, together with age, primary lymph node metastasis, and prehepatectomy chemotherapy. The model performed well in the external validation cohort, with predicted overall survival values almost lying within 10 per cent of observed values. Wild-type RAS was associated with better overall survival than RAS mutation even when liver resection was performed for larger and/or multiple colorectal liver metastases. CONCLUSION The contour prognostic model, based on diameter and number of lesions considered as continuous variables along with RAS mutation, predicts overall survival after resection of colorectal liver metastasis.
Collapse
Affiliation(s)
- Y Kawaguchi
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - S Kopetz
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - H S Tran Cao
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - E Panettieri
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Hepatobiliary Surgery Unit, Foundation and Teaching Hospital IRCCS A. Gemelli, Rome, Italy
| | - M De Bellis
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Department of Surgery, Division of General and Hepatobiliary Surgery, G. B. Rossi University Hospital, University of Verona, Verona, Italy
| | - Y Nishioka
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - H Hwang
- Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - X Wang
- Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - C-W D Tzeng
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Y S Chun
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - T A Aloia
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - K Hasegawa
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - A Guglielmi
- Department of Surgery, Division of General and Hepatobiliary Surgery, G. B. Rossi University Hospital, University of Verona, Verona, Italy
| | - F Giuliante
- Hepatobiliary Surgery Unit, Foundation and Teaching Hospital IRCCS A. Gemelli, Rome, Italy
| | - J-N Vauthey
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
13
|
Nangaku M, Kondo K, Ueta K, Kokado Y, Kaneko G, Matsuda H, Kawaguchi Y, Komatsu Y. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study. Nephrol Dial Transplant 2021; 36:1731-1741. [PMID: 33650630 PMCID: PMC8396402 DOI: 10.1093/ndt/gfab055] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Indexed: 12/17/2022] Open
Abstract
Background Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. Methods The efficacy and safety of vadadustat, compared with darbepoetin alfa, was determined in a Phase 3 double-blind study in Japanese anemic patients on hemodialysis. Patients receiving erythropoiesis-stimulating agents (ESAs) were randomized and switched to either vadadustat or darbepoetin alfa for 52 weeks. Doses were adjusted to maintain a hemoglobin (Hb) level of 10.0–12.0 g/dL. The primary endpoint was average Hb level at Weeks 20 and 24. Results Of the 323 randomized patients, 120 and 135 completed the 52-week treatment period in the vadadustat and darbepoetin alfa groups, respectively. The average Hb levels at Weeks 20 and 24 [least square mean (LSM) and 95% confidence interval (CI)] were 10.61 (10.45–10.76) and 10.65 (10.50–10.80) g/dL in the vadadustat and darbepoetin alfa groups, respectively, demonstrating vadadustat’s noninferiority to darbepoetin alfa (difference: −0.05 g/dL; 95% CI −0.26 to 0.17). In both groups, the mean Hb levels were maintained within the target range for 52 weeks. Furthermore, irrespective of patient backgrounds, the LSMs of Hb at Week 52 were within the target range. The most common adverse events were nasopharyngitis, diarrhea and shunt stenosis, which occurred at similar frequencies in both groups. No new safety concerns were identified. Conclusions Vadadustat was as well-tolerated and effective as darbepoetin alfa in maintaining Hb levels within the target range. The findings suggest that vadadustat can be an alternative to ESA in the management of anemia in Japanese hemodialysis patients receiving ESA (ClinicalTrials.gov, NCT03439137).
Collapse
Affiliation(s)
- Masaomi Nangaku
- Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | | | | | | | - Genki Kaneko
- Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | | | | | - Yasuhiro Komatsu
- Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan
| |
Collapse
|
14
|
Nangaku M, Kondo K, Takabe S, Ueta K, Kaneko G, Otsuka M, Kawaguchi Y, Komatsu Y. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan. Ther Apher Dial 2020; 25:642-653. [PMID: 33283981 PMCID: PMC8451920 DOI: 10.1111/1744-9987.13611] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Revised: 11/27/2020] [Accepted: 12/01/2020] [Indexed: 12/17/2022]
Abstract
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in patients with chronic kidney disease (CKD). This phase 3, open-label, 24-week single-arm study evaluated the efficacy and safety of vadadustat in 42 Japanese CKD patients with anemia undergoing peritoneal dialysis. Patients received oral vadadustat for 24 weeks, initiated at 300 mg/day and doses were adjusted to achieve the target hemoglobin (Hb) range of 11.0-13.0 g/dL. Least squares mean of average Hb at weeks 20 and 24 was 11.35 g/dL, which was within the target range. The most frequent adverse events were catheter site infections (23.8%), which were not related to vadadustat treatment. Vadadustat was generally well tolerated and effective in controlling Hb levels within the target range, indicating the usefulness of vadadustat for treating anemia in Japanese CKD patients undergoing peritoneal dialysis.
Collapse
Affiliation(s)
- Masaomi Nangaku
- Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Kazuoki Kondo
- Integrated Value Development Division, Medical Intelligence Department, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | - Souichirou Takabe
- Integrated Value Development Division, Medical Intelligence Department, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | - Kiichiro Ueta
- Integrated Value Development Division, Medical Intelligence Department, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | - Genki Kaneko
- Integrated Value Development Division, Medical Intelligence Department, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | - Makiko Otsuka
- Integrated Value Development Division, Medical Intelligence Department, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | - Yutaka Kawaguchi
- Integrated Value Development Division, Medical Intelligence Department, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | - Yasuhiro Komatsu
- Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan
| |
Collapse
|
15
|
Miyajima K, Urushida T, Ito K, Kin F, Okazaki A, Takashima Y, Watanabe T, Kawaguchi Y, Wakabayashi Y, Naruse Y, Maekawa Y. Usefulness of lead delivery catheter system for true right ventricular septal pacing. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Right ventricular (RV) septal pacing is often selected to preserve a more physiologic ventricular activation. But the pacing leads are not always located in true septal wall, rather in hinge or free wall in some cases with the conventional stylet-guided lead implantation. In recent years, new guiding catheter systems has attracted attention as a solution to that problem.
Objective
The aim of this study is to investigate that true ventricular sepal pacing can be achieved by use of the new guiding catheter system for pacing lead.
Methods
We enrolled 198 patients who underwent RV septal lead implantation and computed tomography (CT) after pacemaker implantation. 16 cases were used delivery catheter (Delivery), and 182 cases were used stylet for targeting ventricular septum (Conventional). We analyzed the lead locations with CT, and evaluated capture thresholds, R-wave amplitudes, lead impedances and 12-lead electrocardiogram findings one month after implantation.
Results
All cases of delivery catheter group had true septal lead positions (Delivery; 100% vs Conventional; 44%, p<0.01). Capture thresholds and lead impedances had not significant differences between between two groups (0.65±0.15V vs 0.60±0.15V, p=0.21, 570±95Ω vs 595±107Ω, p=0.39, respectively). R-wave amplitudes were significantly higher in delivery catheter group (13.0±4.8mV vs 10±4.6mV, p<0.01). Paced QRS durations were shorter in delivery catheter group (128±16ms vs 150±21ms, p<0.01).
Conclusions
The delivery catheter system designated for pacing lead can contribute to select the true ventricular septal sites and to attain the more physiologic ventricular activation.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Miyajima
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - T Urushida
- Hamamatsu University School of Medicine, The Third Department of Internal Medicine, Hamamatsu, Japan
| | - K Ito
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - F Kin
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - A Okazaki
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - Y Takashima
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - T Watanabe
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - Y Kawaguchi
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - Y Wakabayashi
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - Y Naruse
- Hamamatsu University School of Medicine, The Third Department of Internal Medicine, Hamamatsu, Japan
| | - Y Maekawa
- Hamamatsu University School of Medicine, The Third Department of Internal Medicine, Hamamatsu, Japan
| |
Collapse
|
16
|
Kawaguchi Y, Tzeng CWD, Hasegawa K, Kokudo N, Vauthey JN. Author response to: Comment on: Performance of a modified three-level classification in stratifying open liver resection procedures in terms of complexity and postoperative morbidity. Br J Surg 2020; 107:469. [PMID: 32129492 DOI: 10.1002/bjs.11503] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Accepted: 12/12/2019] [Indexed: 12/16/2022]
Affiliation(s)
- Y Kawaguchi
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - C-W D Tzeng
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - K Hasegawa
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - N Kokudo
- National Center for Global Health and Medicine, Tokyo, Japan
| | - J-N Vauthey
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
17
|
Kawamoto S, Otani K, Kawaguchi Y, Hosoya T. Mycobacterium Fortuitum Peritonitis Associated with Capd: Diagnosis by a Molecular Biology Technique. Perit Dial Int 2020. [DOI: 10.1177/089686089901900618] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Affiliation(s)
- S. Kawamoto
- Department of Internal Medicine II Jikei University School of Medicine 3-25-8 Nishi-Shinbashi, Minato-ku Tokyo, 105 Japan
| | - K. Otani
- Department of Internal Medicine II Jikei University School of Medicine 3-25-8 Nishi-Shinbashi, Minato-ku Tokyo, 105 Japan
| | - Y. Kawaguchi
- Department of Internal Medicine II Jikei University School of Medicine 3-25-8 Nishi-Shinbashi, Minato-ku Tokyo, 105 Japan
| | - T. Hosoya
- Department of Internal Medicine II Jikei University School of Medicine 3-25-8 Nishi-Shinbashi, Minato-ku Tokyo, 105 Japan
| |
Collapse
|
18
|
Nishino A, Katsumata Y, Kawasumi H, Hirahara S, Kawaguchi Y, Yamanaka H. Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus. Lupus 2020; 28:986-994. [PMID: 31246559 DOI: 10.1177/0961203319860201] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE We aimed to study the usefulness of serum soluble CD163 (sCD163) as a biomarker for macrophage activation syndrome (MAS) associated with systemic lupus erythematosus (SLE). METHODS Serum sCD163 levels were retrospectively measured by enzyme-linked immunosorbent assay for SLE patients associated with MAS (SLE-MAS), lupus nephritis (LN), or autoimmune hemolytic anemia (AIHA) and/or immune thrombocytopenia (ITP) and healthy controls (HCs). Posttreatment samples were also evaluated in the available SLE-MAS patients. The associations between serum sCD163 levels and clinical information were statistically analyzed. RESULTS The serum sCD163 levels in SLE-MAS, LN and SLE-AIHA/ITP groups were significantly higher than those in HCs (n = 17, 29, 13, and 68, respectively; p < 0.01 for all comparisons). In addition, the serum sCD163 levels in the SLE-MAS group were even higher than those in the LN and SLE-AIHA/ITP groups (p < 0.01 for both comparisons). Serum sCD163 levels were correlated with the SLE Disease Activity Index 2000 scores (r = 0.53), whereas they were not correlated with the serum ferritin levels. With the determined cut-off value, the sensitivity and specificity of serum sCD163 for the diagnosis of SLE-MAS were 59% and 86%, respectively. Retesting showed that the serum sCD163 levels decreased significantly following treatment in parallel with disease amelioration in the SLE-MAS group (p < 0.01). CONCLUSIONS The present study suggests the usefulness of serum sCD163 as a diagnostic and disease-activity biomarker for SLE-associated MAS. Serum sCD163 might also have a different role as a biomarker for SLE-associated MAS than serum ferritin does.
Collapse
Affiliation(s)
- A Nishino
- Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| | - Y Katsumata
- Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| | - H Kawasumi
- Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| | - S Hirahara
- Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| | - Y Kawaguchi
- Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| | - H Yamanaka
- Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| |
Collapse
|
19
|
Kawaguchi Y, Hasegawa K, Tzeng CWD, Mizuno T, Arita J, Sakamoto Y, Chun YS, Aloia TA, Kokudo N, Vauthey JN. Performance of a modified three-level classification in stratifying open liver resection procedures in terms of complexity and postoperative morbidity. Br J Surg 2019; 107:258-267. [PMID: 31603540 DOI: 10.1002/bjs.11351] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 08/05/2019] [Accepted: 08/06/2019] [Indexed: 01/05/2023]
Abstract
BACKGROUND Traditional classifications for open liver resection are not always associated with surgical complexity and postoperative morbidity. The aim of this study was to test whether a three-level classification for stratifying surgical complexity based on surgical and postoperative outcomes, originally devised for laparoscopic liver resection, is superior to classifications based on a previously reported survey for stratifying surgical complexity of open liver resections, minor/major nomenclature or number of resected segments. METHODS Patients undergoing a first open liver resection without simultaneous procedures at MD Anderson Cancer Center (Houston cohort) or the University of Tokyo (Tokyo cohort) were studied. Surgical and postoperative outcomes were compared among three grades: I (wedge resection for anterolateral or posterosuperior segment and left lateral sectionectomy); II (anterolateral segmentectomy and left hepatectomy); III (posterosuperior segmentectomy, right posterior sectionectomy, right hepatectomy, central hepatectomy and extended left/right hepatectomy). RESULTS In both the Houston (1878 patients) and Tokyo (1202) cohorts, duration of operation, estimated blood loss and comprehensive complication index score differed between the three grades (all P < 0·050) and increased in stepwise fashion from grades I to III (all P < 0·001). Left hepatectomy was associated with better surgical and postoperative outcomes than right hepatectomy, extended right hepatectomy and right posterior sectionectomy, although these four procedures were categorized as being of medium complexity in the survey-based classification. Surgical outcomes of minor open liver resections also differed between the three grades (all P < 0·050). For duration of operation and blood loss, the area under the curve was higher for the three-level classification than for the minor/major or segment-based classification. CONCLUSION The three-level classification may be useful in studies analysing open liver resection at Western and Eastern centres.
Collapse
Affiliation(s)
- Y Kawaguchi
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - K Hasegawa
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - C-W D Tzeng
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - T Mizuno
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - J Arita
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Y Sakamoto
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Y S Chun
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - T A Aloia
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - N Kokudo
- National Centre for Global Health and Medicine, Tokyo, Japan
| | - J-N Vauthey
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
20
|
Kawaguchi Y, Nakao M, Ichinose J, Matsuura Y, Okumura S, Mun M. P2.13-14 The Utility of Three-Dimensional CT for Prediction of Tumor Invasiveness in Clinical IA Lung Acenocarcinoma. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Aoshima C, Fujimoto S, Kawaguchi Y, Dohi T, Kato E, Takamura K, Kamo Y, Hiki M, Kato Y, Okai I, Okazaki S, Kumamaru K, Daida H. P6173Plaque characteristics on coronary CT angiography in case of discordance between fractional flow reserve (FFR) and instantaneous wave-free ratio (IFR). Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The usefulness of fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) evaluation has been confirmed in the determination of revascularization of coronary artery disease. When FFR≤0.8 and iFR≤0.89 were regarded as the criteria for positivity, the discordance was noted in approximately 20%, but this cause has not been well established.
Purpose
The purpose of this study was to investigate the patient background and features on coronary CT angiography (CCTA) showing the discordance between FFR≤0.8 and iFR≤0.89.
Methods
The subjects were consecutive 85 cases with 108 vessels in which stenosis of 30–90% was detected at one vessel of at least 2mm or more in the major epicardial vessels and FFR and iFR was performed within subsequent 90 days, among suspected cases of coronary arterial diseases which underwent CCTA. The factors showing the discordance between FFR and iFR (patient background, coronary artery calcification score, high risk plaque features on CCTA (positive remodeling, low attenuation plaque), plaque characteristics by a plaque analysis software using a new algorithm called labeling method (vessel volume, plaque volume, lumen volume, plaque length, maximum plaque burden, necrotic core area, fibrous area and calcium area) were evaluated using logistic regression analysis on per-patient and per-vessel basis.
Results
There were no significant both FFR and iFR positive definite factors on per-patient basis. The lumen volume/vessel volume (OR: 0.93, 95% CI: 0.88–0.98, P=0.0032) (OR: 0.90, 95% CI: 0.85–0.95, P<0.0001),minimum lumen area (MLA) (OR: 0.59, 95% CI: 0.41–0.85, P=0.0006) (OR: 0.64, 95% CI: 0.44–0.92, P=0.0047), the plaque volume/vessel volume (OR: 1.05, 95% CI: 1.01–1.10, P=0.0114) (OR: 1.09, 95% CI: 1.04–1.15, P=0.0002) and maximum plaque burden (OR: 1.08, 95% CI: 1.01–1.15, P=0.0095) (OR: 1.06, 95% CI: 1.00–1.13, P=0.0406) were significant both FFR and iFR positive definite factors on per-vessels basis. Discordance between FFR≤0.8 and iFR≤0.89 was observed in 23 vessels (21.3%) of 19 patients. In FFR positive and iFR negative group (15 vessels, 13.9%), positive remodeling (PR) (OR: 4.38, 95% CI: 1.13–17.00, P=0.0294) was only significant predictor. In FFR negative and iFR positive group, there was no significant predictors.
Conclusions
In both FFR and iFR, only lumen volume /vessel volume, MLA, plaque volume/vessel volume and plaque burden were significant positive definite factors. As for the discordance between FFR and iFR, PR is significant predictor in FFR positive and iFR negative group.
Collapse
Affiliation(s)
- C Aoshima
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - S Fujimoto
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Y Kawaguchi
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - T Dohi
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - E Kato
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - K Takamura
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Y Kamo
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - M Hiki
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Y Kato
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - I Okai
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - S Okazaki
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - K Kumamaru
- Juntendo University Graduate School of Medicine, Radiology, Tokyo, Japan
| | - H Daida
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| |
Collapse
|
22
|
Miyajima K, Shirai Y, Kin F, Watanabe T, Tatsuguchi M, Kawaguchi Y, Wakabayashi Y. P52714D-flow cardiac magnetic resonance analysis of left ventricular blood flow dynamics in mid-ventricular obstructive hypertrophic cardiomyopathy. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Mid-ventricular obstructive hypertrophic cardiomyopathy (MVO-HCM) has different blood flow dynamics from other phenotypes, but there are few detailed data on blood flow dynamics in the left ventricle.
Methods
4D-Flow MRI were performed at 1.5 T or 3 T with 9 MVO-HCM patients and 22 control patients (LVEF>50%, no wall motion abnormality). Myocardial infarction, severe valvular disease, HCM cases other than MVO were excluded. We calculated the cardiac function parameters and observed blood flow dynamics in the left ventricle using 4D-Flow MRI.
Results
LV mass was significantly higher in MVO-HCM group than in Control group (Control group; 73.3g vs MVO-HCM group; 109.5g, P=0.019). LVEF was higher in MVO-HCM group (Control group; 61.6% vs MVO-HCM group; 70.6%, P=0.026), but Stroke volume did not differ between the two groups (Control group; 68.8ml vs MVO-HCM group; 64.4ml, P=0.43).One or two vortices were observed in the left ventricle after opening the mitral valve. Two vortices were observed in 16 cases (72.7%) in the control group and 9 cases (100%) in the MVO-HCM group. Two vortices were formed on the anterior side and the posterior side. Blood flow pattern in which the vortex on the posterior side was formed to be the same size or larger than the vortex on the anterior side was observed only in the MVO-HCM group (Control group; 0% vs MVO-HCM group; 66.7%, P<0.001).
Streamline of MVO-HCM & Control
Conclusion
Characteristic blood flow patterns in the left ventricle of the MVO-HCM were revealed by using 4D-MRI. We thought that blood flow collides with the left ventricle wall due to the marked hypertrophy in the mid-ventricle, and normal vortex ring can not be formed in the MVO-HCM cases.
Collapse
Affiliation(s)
- K Miyajima
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - Y Shirai
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - F Kin
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - T Watanabe
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - M Tatsuguchi
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - Y Kawaguchi
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| | - Y Wakabayashi
- Seirei Mikatahara General Hospital, Cardiology, Hamamatsu, Japan
| |
Collapse
|
23
|
Nagase T, Komatsu M, So YG, Ishida T, Yoshida H, Kawaguchi Y, Tanaka Y, Saitoh K, Ikarashi N, Kuwahara M, Nagao M. Smectic Liquid-Crystalline Structure of Skyrmions in Chiral Magnet Co_{8.5}Zn_{7.5}Mn_{4}(110) Thin Film. Phys Rev Lett 2019; 123:137203. [PMID: 31697552 DOI: 10.1103/physrevlett.123.137203] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Indexed: 06/10/2023]
Abstract
The organizing of magnetic skyrmions shows several forms similar to atomic arrays of solid states. Using Lorentz transmission electron microscopy, we report the first direct observation of a stable liquid-crystalline structure of skyrmions in chiral magnet Co_{8.5}Zn_{7.5}Mn_{4}(110) thin film, caused by magnetic anisotropy and chiral surface twist. Elongated skyrmions are oriented and periodically arranged only in the ⟨110⟩ directions, whereas they exhibit short-range order along the ⟨001⟩ directions, indicating a smectic skyrmion state. In addition, skyrmions possess anisotropic interaction with an opposite sign depending on the crystal orientation, in contrast to existing isotropic interaction.
Collapse
Affiliation(s)
- T Nagase
- Department of Electrical, Electronic Engineering and Information Engineering, School of Engineering, Nagoya University, Nagoya 464-8601, Japan
| | - M Komatsu
- Department of Materials Science, Graduate School of Engineering Science, Akita University, Akita 010-8502, Japan
| | - Y G So
- Department of Materials Science, Graduate School of Engineering Science, Akita University, Akita 010-8502, Japan
| | - T Ishida
- Advanced Measurement Technology Center, Institute of Materials and Systems for Sustainability, Nagoya University, Nagoya 464-8601, Japan
| | - H Yoshida
- Department of Physics, Hokkaido University, Sapporo 060-0810, Japan
| | - Y Kawaguchi
- Department of Applied Physics, Graduate School of Engineering, Nagoya University, Nagoya 464-8601, Japan
| | - Y Tanaka
- Department of Applied Physics, Graduate School of Engineering, Nagoya University, Nagoya 464-8601, Japan
| | - K Saitoh
- Advanced Measurement Technology Center, Institute of Materials and Systems for Sustainability, Nagoya University, Nagoya 464-8601, Japan
| | - N Ikarashi
- Center for Integrated Research of Future Electronics, Institute of Materials and Systems for Sustainability, Nagoya University, Nagoya 464-8601, Japan
- Department of Electronics, Graduate School of Engineering, Nagoya University, Nagoya 464-8603, Japan
| | - M Kuwahara
- Advanced Measurement Technology Center, Institute of Materials and Systems for Sustainability, Nagoya University, Nagoya 464-8601, Japan
| | - M Nagao
- Center for Integrated Research of Future Electronics, Institute of Materials and Systems for Sustainability, Nagoya University, Nagoya 464-8601, Japan
- Department of Electronics, Graduate School of Engineering, Nagoya University, Nagoya 464-8603, Japan
| |
Collapse
|
24
|
Nakata Y, Furuya S, Shimizu H, Akaike H, Hosomura N, Kawaguchi Y, Amemiya H, Sudo M, Kawaida H, Inoue S, Kono H, Ichikawa D. MON-PO416: Effects of Preoperative Skeletal Muscle Mass and Neutrophil Lymphocyte Ratio on the Prognosis of Stage II and III Colorectal Cancer. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32249-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
25
|
Furuya S, Ashizawa N, Nakata Y, Shimizu H, Akaike H, Hosomura N, Kawaguchi Y, Amemiya H, Sudo M, Kawaida H, Inoue S, Kono H, Ichikawa D. MON-PO398: Examination of Immune-Nutritional Index Before and After Surgery and Prognosis for Colon Cancer Patients: Possibility to Nutritional Precision Medicine. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32231-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
26
|
Sai E, Shimada K, Yokoyama T, Hiki M, Aikawa T, Ouchi S, Aoshima C, Kawaguchi Y, Miyazaki T, Fujimoto S, Tamura Y, Aoki S, Watada H, Kawamori R, Daida H. P192Associations between ectopic fat accumulations and cardio-metabolic factors in apparently healthy subjects: assessed by 1H-magnetic resonance spectroscopy in myocardium, liver, and skeletal muscles. Eur Heart J Cardiovasc Imaging 2019. [DOI: 10.1093/ehjci/jez117.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- E Sai
- Juntendo University Graduate School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - K Shimada
- Juntendo University Graduate School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - T Yokoyama
- Juntendo University Graduate School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - M Hiki
- Juntendo University Graduate School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - T Aikawa
- Juntendo University Graduate School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - S Ouchi
- Juntendo University Graduate School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - C Aoshima
- Juntendo University Graduate School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - Y Kawaguchi
- Juntendo University Graduate School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - T Miyazaki
- Juntendo University Graduate School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - S Fujimoto
- Juntendo University Graduate School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - Y Tamura
- Juntendo University Graduate School of Medicine, Department of Metabolism and Endocrinology, Tokyo, Japan
| | - S Aoki
- Juntendo University Graduate School of Medicine, Department of Radiology, Tokyo, Japan
| | - H Watada
- Juntendo University Graduate School of Medicine, Department of Metabolism and Endocrinology, Tokyo, Japan
| | - R Kawamori
- Juntendo University Graduate School of Medicine, Department of Metabolism and Endocrinology, Tokyo, Japan
| | - H Daida
- Juntendo University Graduate School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| |
Collapse
|
27
|
Nozaki M, Kagami Y, Takahashi M, Machida R, Shibata T, Ito Y, Nishimura Y, Kawaguchi Y, Saito Y, Nagata Y, Matsumoto Y, Akimoto T, Hoiraoka M. EP-1276 A Comparison of Breast Cosmetic Evaluation Methods in Hypofractionated Whole Breast Irradiation. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31696-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
28
|
Chen PK, Liu LR, Tsai MJ, Chiu NC, Kawaguchi Y, Yip SK, Chang MS, Lin YJ. Rotating Atomic Quantum Gases with Light-Induced Azimuthal Gauge Potentials and the Observation of the Hess-Fairbank Effect. Phys Rev Lett 2018; 121:250401. [PMID: 30608846 DOI: 10.1103/physrevlett.121.250401] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Indexed: 06/09/2023]
Abstract
We demonstrate synthetic azimuthal gauge potentials for Bose-Einstein condensates from engineering atom-light couplings. The gauge potential is created by adiabatically loading the condensate into the lowest energy Raman-dressed state, achieving a coreless vortex state. The azimuthal gauge potentials act as effective rotations and are tunable by the Raman coupling and detuning. We characterize the spin textures of the dressed states, in agreements with the theory. The lowest energy dressed state is stable with a 4.5-s half-atom-number-fraction lifetime. In addition, we exploit the azimuthal gauge potential to demonstrate the Hess-Fairbank effect, the analogue of Meissner effect in superconductors. The atoms in the absolute ground state has a zero quasiangular momentum and transits into a polar-core vortex when the synthetic magnetic flux is tuned to exceed a critical value. Our demonstration serves as a paradigm to create topological excitations by tailoring atom-light interactions where both types of SO(3) vortices in the |⟨F[over →]⟩|=1 manifold, coreless vortices and polar-core vortices, are created in our experiment. The gauge field in the stationary Hamiltonian opens a path to investigating rotation properties of atomic superfluids under thermal equilibrium.
Collapse
Affiliation(s)
- P-K Chen
- Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei 10617, Taiwan
| | - L-R Liu
- Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei 10617, Taiwan
| | - M-J Tsai
- Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei 10617, Taiwan
| | - N-C Chiu
- Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei 10617, Taiwan
| | - Y Kawaguchi
- Department of Applied Physics, Nagoya University, Nagoya 464-8603, Japan
| | - S-K Yip
- Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei 10617, Taiwan
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
- National Center for Theoretical Sciences, Hsinchu 300, Taiwan
| | - M-S Chang
- Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei 10617, Taiwan
| | - Y-J Lin
- Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei 10617, Taiwan
| |
Collapse
|
29
|
Kaneko N, Herranz-Pérez V, Otsuka T, Sano H, Ohno N, Omata T, Nguyen HB, Thai TQ, Nambu A, Kawaguchi Y, García-Verdugo JM, Sawamoto K. New neurons use Slit-Robo signaling to migrate through the glial meshwork and approach a lesion for functional regeneration. Sci Adv 2018; 4:eaav0618. [PMID: 30547091 PMCID: PMC6291311 DOI: 10.1126/sciadv.aav0618] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Accepted: 11/11/2018] [Indexed: 06/09/2023]
Abstract
After brain injury, neural stem cell-derived neuronal precursors (neuroblasts) in the ventricular-subventricular zone migrate toward the lesion. However, the ability of the mammalian brain to regenerate neuronal circuits for functional recovery is quite limited. Here, using a mouse model for ischemic stroke, we show that neuroblast migration is restricted by reactive astrocytes in and around the lesion. To migrate, the neuroblasts use Slit1-Robo2 signaling to disrupt the actin cytoskeleton in reactive astrocytes at the site of contact. Slit1-overexpressing neuroblasts transplanted into the poststroke brain migrated closer to the lesion than did control neuroblasts. These neuroblasts matured into striatal neurons and efficiently regenerated neuronal circuits, resulting in functional recovery in the poststroke mice. These results suggest that the positioning of new neurons will be critical for functional neuronal regeneration in stem/progenitor cell-based therapies for brain injury.
Collapse
Affiliation(s)
- N. Kaneko
- Department of Developmental and Regenerative Biology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan
| | - V. Herranz-Pérez
- Laboratory of Comparative Neurobiology, Instituto Cavanilles, Universidad de Valencia, CIBERNED, C/Catedrático José Beltrán, 2, Paterna, 46980 Valencia, Spain
- Predepartamental Unit of Medicine, Faculty of Health Sciences, Universitat Jaume I, Q-6250003-H Av. de Vicent Sos Baynat, s/n, 12071 Castelló de la Plana, Spain
| | - T. Otsuka
- Division of Cerebral Circuitry, National Institute for Physiological Sciences, 5-1 Higashiyama, Myodaiji, Okazaki, Aichi 444-8787, Japan
- Department of Physiological Sciences, SOKENDAI (The Graduate University for Advanced Studies), Okazaki, Aichi 444-8585, Japan
| | - H. Sano
- Department of Physiological Sciences, SOKENDAI (The Graduate University for Advanced Studies), Okazaki, Aichi 444-8585, Japan
- Division of System Neurophysiology, National Institute for Physiological Sciences, 38 Nishigonaka, Myodaiji, Okazaki, Aichi 444-8585, Japan
| | - N. Ohno
- Department of Anatomy, Division of Histology and Cell Biology, Jichi Medical University, School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
- Division of Neurobiology and Bioinformatics, National Institute for Physiological Sciences, 5-1 Higashiyama, Myodaiji, Okazaki, Aichi 444-8787, Japan
| | - T. Omata
- Department of Developmental and Regenerative Biology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan
| | - H. B. Nguyen
- Division of Neurobiology and Bioinformatics, National Institute for Physiological Sciences, 5-1 Higashiyama, Myodaiji, Okazaki, Aichi 444-8787, Japan
- Department of Anatomy, Faculty of Medicine, University of Medicine and Pharmacy (UMP), Ho Chi Minh City 700000, Vietnam
| | - T. Q. Thai
- Division of Neurobiology and Bioinformatics, National Institute for Physiological Sciences, 5-1 Higashiyama, Myodaiji, Okazaki, Aichi 444-8787, Japan
| | - A. Nambu
- Department of Physiological Sciences, SOKENDAI (The Graduate University for Advanced Studies), Okazaki, Aichi 444-8585, Japan
- Division of System Neurophysiology, National Institute for Physiological Sciences, 38 Nishigonaka, Myodaiji, Okazaki, Aichi 444-8585, Japan
| | - Y. Kawaguchi
- Division of Cerebral Circuitry, National Institute for Physiological Sciences, 5-1 Higashiyama, Myodaiji, Okazaki, Aichi 444-8787, Japan
- Department of Physiological Sciences, SOKENDAI (The Graduate University for Advanced Studies), Okazaki, Aichi 444-8585, Japan
| | - J. M. García-Verdugo
- Laboratory of Comparative Neurobiology, Instituto Cavanilles, Universidad de Valencia, CIBERNED, C/Catedrático José Beltrán, 2, Paterna, 46980 Valencia, Spain
| | - K. Sawamoto
- Department of Developmental and Regenerative Biology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan
- Division of Neural Development and Regeneration, National Institute for Physiological Sciences, 5-1 Higashiyama, Myodaiji, Okazaki, Aichi 444-8787, Japan
| |
Collapse
|
30
|
Kawaguchi Y, Nozaki M, Kagami Y, Shibata T, Nakamura K, Ito Y, Nishimura Y, Saito Y, Nagata Y, Matsumo Y, Akimoto T, Nishimura T, Uno T, Tsujino K, Kataoka M, Kodaira T, Shiraishi K, Inoue K, Isohashi F, Hiraoka M. A Multicenter Single-Arm Confirmatory Trial on Hypofractionated Whole-breast Irradiation after Breast-Conserving Surgery. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Shitara K, Bang YJ, Sakai D, Yasui H, Kawaguchi Y, Sugihara M, Saito K, Dalal R, Yamaguchi K. A randomized, phase II, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Sugita Y, Miyazaki T, Shimizu M, Kunimoto M, Aikawa T, Ouchi S, Kadoguchi T, Kawaguchi Y, Shiozawa T, Takahashi S, Hiki M, Yokoyama M, Iwata H, Shimada K, Daida H. P6275Malnutrition and low omega 6 PUFA levels on admission were associated with the development of delirium in patients with acute cardiovascular disease admitted to coronary care unit. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Y Sugita
- Juntendo University, Tokyo, Japan
| | | | | | | | - T Aikawa
- Juntendo University, Tokyo, Japan
| | - S Ouchi
- Juntendo University, Tokyo, Japan
| | | | | | | | | | - M Hiki
- Juntendo University, Tokyo, Japan
| | | | - H Iwata
- Juntendo University, Tokyo, Japan
| | | | - H Daida
- Juntendo University, Tokyo, Japan
| |
Collapse
|
33
|
Kato E, Fujimoto S, Kawaguchi Y, Kumamaru K, Dohi T, Takamura K, Aoshima C, Hiki M, Kato Y, Okazaki S, Daida H. 3286Incremental diagnostic value of CT-fractional flow reserve using subtraction coronary CT angiography for patients with severe calcification. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.3286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- E Kato
- Juntendo University, Cardiology, Tokyo, Japan
| | - S Fujimoto
- Juntendo University, Cardiology, Tokyo, Japan
| | - Y Kawaguchi
- Juntendo University, Cardiology, Tokyo, Japan
| | - K Kumamaru
- Juntendo University, Radiology, Tokyo, Japan
| | - T Dohi
- Juntendo University, Cardiology, Tokyo, Japan
| | - K Takamura
- Juntendo University, Cardiology, Tokyo, Japan
| | - C Aoshima
- Juntendo University, Cardiology, Tokyo, Japan
| | - M Hiki
- Juntendo University, Cardiology, Tokyo, Japan
| | - Y Kato
- Juntendo University, Cardiology, Tokyo, Japan
| | - S Okazaki
- Juntendo University, Cardiology, Tokyo, Japan
| | - H Daida
- Juntendo University, Cardiology, Tokyo, Japan
| |
Collapse
|
34
|
Harashima S, Inagaki N, Kondo K, Maruyama N, Otsuka M, Kawaguchi Y, Watanabe Y. Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study. Diabetes Obes Metab 2018; 20:1770-1775. [PMID: 29473709 PMCID: PMC6033027 DOI: 10.1111/dom.13267] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2017] [Revised: 02/16/2018] [Accepted: 02/19/2018] [Indexed: 12/13/2022]
Abstract
Sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are antihyperglycaemic agents with weight-lowering effects. The efficacy and safety of the SGLT2 inhibitor canagliflozin as add-on therapy in Japanese patients with type 2 diabetes mellitus (T2DM) and inadequate glycaemic control with a GLP-1RA (≥12 weeks) were evaluated in this phase IV study. Patients received canagliflozin 100 mg once daily for 52 weeks. Efficacy endpoints included change in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP) and HDL cholesterol from baseline to week 52. Safety endpoints included adverse events (AEs), hypoglycaemia and laboratory tests. Of the 71 patients treated with canagliflozin, 63 completed the study. At 52 weeks, HbA1c was significantly reduced from baseline (-0.70%; paired t test, P < .001). Significant changes were also observed in FPG (-34.7 mg/dL), body weight (-4.46%), SBP (-7.90 mm Hg), and HDL cholesterol (7.60%; all P < .001). The incidence of AEs, adverse drug reactions and hypoglycaemia was 71.8%, 32.4% and 9.9%, respectively. All hypoglycaemic events were mild. These findings suggest that the long-term combination of canagliflozin with a GLP-1RA is effective and well tolerated in Japanese patients with T2DM.
Collapse
Affiliation(s)
- Shin‐ichi Harashima
- Department of Diabetes, Endocrinology and NutritionKyoto University Graduate School of MedicineKyotoJapan
| | - Nobuya Inagaki
- Department of Diabetes, Endocrinology and NutritionKyoto University Graduate School of MedicineKyotoJapan
| | - Kazuoki Kondo
- Ikuyaku Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Nobuko Maruyama
- Ikuyaku Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Makiko Otsuka
- Ikuyaku Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Yutaka Kawaguchi
- Ikuyaku Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Yumi Watanabe
- Ikuyaku Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| |
Collapse
|
35
|
Akizawa T, Koshikawa S, Takaku F, Urabe A, Akiyama N, Mimura N, Otsubo O, Nihei H, Suzuki Y, Kawaguchi Y, Ota K, Kubo K, Marumo F, Maeda T. Clinical Effect of Recombinant Human Erythropoietin on Anemia Associated with Chronic Renal Failure. A Multiinstitutional Study in Japan. Int J Artif Organs 2018. [DOI: 10.1177/039139888801100507] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Clinical effect and safety of recombinant human erythropoietin (r-HuEPO) were evaluated in 66 hemodialysis patients with intractable anemia. Initially, 50U/kg dry weight (DW) of r-HuEPO was administered intravenously at the end of every hemodialysis procedure for 4 weeks, then the dosage was increased to 100 and 200U/kg DW for poor responders. The patients’ hematocrits rose from 19.8 ± 2.3% (pretreatment) to 30.2 ± 4.9% after 12 weeks. From 206 U of blood transfusion requirement in the 3-month period before the study, only 34 U were needed after treatment. Serum iron and ferritin levels fell significantly during the study, and iron storage was considered to be one of the decisive factors in the response to r-HuEPO. Blood pressure rose in the course of r-HuEPO administration, but uncontrollable hypertension was rarely observed. There was no significant adverse effect of r-HuEPO except for this mild hypertension. These results indicate that r-HuEPO is an excellent therapeutic aid for the anemia associated with chronic renal failure.
Collapse
Affiliation(s)
- T. Akizawa
- Fujigaoka Hospital, Showa University Yokohama - Japan
| | - S. Koshikawa
- Fujigaoka Hospital, Showa University Yokohama - Japan
| | | | | | | | | | | | | | | | | | - K. Ota
- Tokyo Women's Medical College, Tokyo
| | - K. Kubo
- Tokyo Women's Medical College, Tokyo
| | | | - T. Maeda
- Kanto Rosai Hospital, Kawasaki - Japan
| |
Collapse
|
36
|
Inagaki N, Harashima S, Kaku K, Kondo K, Maruyama N, Otsuka M, Kawaguchi Y, Iijima H. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2018; 20:812-820. [PMID: 29110384 PMCID: PMC5873413 DOI: 10.1111/dom.13152] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Revised: 10/20/2017] [Accepted: 10/31/2017] [Indexed: 12/11/2022]
Abstract
AIM The aim of this study was to assess the long-term efficacy and safety of canagliflozin as add-on therapy in Japanese patients with type 2 diabetes mellitus who had inadequate glycaemic control with insulin. MATERIALS AND METHODS The study comprised a 16-week, double-blind period in which patients were randomized to either placebo (P; N = 70) or canagliflozin (100 mg, CAN; N = 76), followed by a 36-week open-label period in which all patients received canagliflozin. The efficacy endpoints included the change in HbA1c from baseline to end of treatment. The safety endpoints were adverse events, hypoglycaemic events, and laboratory test values. RESULTS The changes from baseline (mean ± standard deviation, last observation carried forward) in the P/CAN and CAN/CAN groups, respectively, were -1.09% ± 0.85% and -0.88% ± 0.86% for HbA1c, -1.40% ± 2.54% and -2.14% ± 2.75% for body weight, and 7.84% ± 14.37% and 8.91% ± 10.80% for HOMA2-%B (all, P < .001). Adverse events occurred in 85.1% of the P/CAN group and 92.0% of the CAN/CAN group. Hypoglycaemic events occurred in 43.3% and 54.7%, respectively. All hypoglycaemic events were mild in severity and insulin dose reduction decreased the incidence rate of hypoglycaemic events. Post-hoc ordinal logistic modelling/logistic modelling showed that lower serum C-peptide at Week 0 was a risk factor for hypoglycaemia in both the P and CAN groups in the double-blind period as well as in the canagliflozin all-treatment period. CONCLUSIONS This study demonstrates the long-term efficacy and safety of canagliflozin combined with insulin in Japanese patients.
Collapse
Affiliation(s)
- Nobuya Inagaki
- Department of Diabetes, Endocrinology and NutritionKyoto University Graduate School of MedicineKyotoJapan
| | - Shin‐ichi Harashima
- Department of Diabetes, Endocrinology and NutritionKyoto University Graduate School of MedicineKyotoJapan
| | - Kohei Kaku
- Department of General Internal Medicine 1Kawasaki Medical SchoolOkayamaJapan
| | - Kazuoki Kondo
- Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Nobuko Maruyama
- Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Makiko Otsuka
- Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Yutaka Kawaguchi
- Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Hiroaki Iijima
- Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma CorporationTokyoJapan
| |
Collapse
|
37
|
Ueno M, Shimazu T, Sawada N, Tsugane S, Kawaguchi Y. Validity of self-reported tooth counts and masticatory status study of a Japanese adult population. J Oral Rehabil 2018; 45:393-398. [DOI: 10.1111/joor.12615] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/31/2018] [Indexed: 11/28/2022]
Affiliation(s)
- M. Ueno
- Department of Oral Health Promotion; Tokyo Medical and Dental University; Tokyo Japan
| | - T. Shimazu
- Epidemiology and Prevention Group; Center for Public Health Sciences; National Cancer Center; Tokyo Japan
| | - N. Sawada
- Epidemiology and Prevention Group; Center for Public Health Sciences; National Cancer Center; Tokyo Japan
| | - S. Tsugane
- Epidemiology and Prevention Group; Center for Public Health Sciences; National Cancer Center; Tokyo Japan
| | - Y. Kawaguchi
- Department of Oral Health Promotion; Tokyo Medical and Dental University; Tokyo Japan
| |
Collapse
|
38
|
Ohshio Y, Hayashi K, Okamoto K, Kaku R, Kataoka Y, Kawaguchi Y, Ohshio M, Igarashi T, Hashimoto M, Teramoto K, Hanaoka J. P1.02-030 The Effect of Chronic Obstructive Pulmonary Disease on the Tumor Stroma in Non-Small Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Igarashi T, Hayashi K, Okamoto K, Kaku R, Kataoka Y, Kawaguchi Y, Hashimoto M, Ohshio Y, Teramoto K, Hanaoka J. P3.16-048 The Role of Pulmonary Resection in Stage IVa Non-Small Cell Carcinoma Patients. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
40
|
Nakajima E, Sugita M, Furukawa K, Takahashi H, Kawaguchi Y, Ohira T, Ikeda N, Hirsch F, Franklin W. P2.03-019 Sizing Capillary Electrophoresis with PCR to Detect Various EGFR Exon 19 Deletions in Non-Small Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
41
|
Teramoto K, Namura Y, Hayashi K, Ishida K, Ueda K, Okamoto K, Kaku R, Hori T, Kawaguchi Y, Igarashi T, Hashimoto M, Ohshio Y, Kitamura S, Motoishi M, Suzumura Y, Sawai S, Hanaoka J, Daigo Y. P1.03-037 A Phase II Study of Adjuvant Chemotherapy with Docetaxel plus Nedaplatin for Completely Resected Non-Small Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
42
|
Wada K, Kishi N, Kanayama N, Hirata T, Kawaguchi Y, Konishi K, Teshima T. Predictors Associated with Severe Acute Esophagitis in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Concomitant Boost Chemoradiation. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
43
|
Kawauchi D, Ogg RJ, Liu L, Shih DJH, Finkelstein D, Murphy BL, Rehg JE, Korshunov A, Calabrese C, Zindy F, Phoenix T, Kawaguchi Y, Gronych J, Gilbertson RJ, Lichter P, Gajjar A, Kool M, Northcott PA, Pfister SM, Roussel MF. Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. Oncogene 2017; 36:5231-5242. [PMID: 28504719 PMCID: PMC5605674 DOI: 10.1038/onc.2017.110] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2016] [Revised: 02/22/2017] [Accepted: 03/12/2017] [Indexed: 12/17/2022]
Abstract
Group3 medulloblastoma (MBG3) that predominantly occur in young children are usually associated with MYC amplification and/or overexpression, frequent metastasis and a dismal prognosis. Physiologically relevant MBG3 models are currently lacking, making inferences related to their cellular origin thus far limited. Using in utero electroporation, we here report that MBG3 mouse models can be developed in situ from different multipotent embryonic cerebellar progenitor cells via conditional expression of Myc and loss of Trp53 function in several Cre driver mouse lines. The Blbp-Cre driver that targets embryonic neural progenitors induced tumors exhibiting a large-cell/anaplastic histopathology adjacent to the fourth ventricle, recapitulating human MBG3. Enforced co-expression of luciferase together with Myc and a dominant-negative form of Trp53 revealed that GABAergic neuronal progenitors as well as cerebellar granule cells give rise to MBG3 with their distinct growth kinetics. Cross-species gene expression analysis revealed that these novel MBG3 models shared molecular characteristics with human MBG3, irrespective of their cellular origin. We here developed MBG3 mouse models in their physiological environment and we show that oncogenic insults drive this MB subgroup in different cerebellar lineages rather than in a specific cell of origin.
Collapse
Affiliation(s)
- D Kawauchi
- Department of Tumor Cell Biology, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
- Division of Pediatric Neuro-Oncology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
| | - R J Ogg
- Department of Radiological Sciences, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
| | - L Liu
- Department of Tumor Cell Biology, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
| | - D J H Shih
- The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, Toronto, ON, Canada
| | - D Finkelstein
- Department of Computational Biology, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
| | - B L Murphy
- Department of Tumor Cell Biology, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
| | - J E Rehg
- Department of Veterinary Pathology Core, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
| | - A Korshunov
- Clinical Cooperation Unit Neuropathology, German Cancer Research Centre (DKFZ), Department of Neuropathology, University of Heidelberg, Heidelberg, Germany
| | - C Calabrese
- Department of Small Animal Imaging Core, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
| | - F Zindy
- Department of Tumor Cell Biology, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
| | - T Phoenix
- Department of Developmental Neurobiology, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
| | - Y Kawaguchi
- Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
| | - J Gronych
- Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - R J Gilbertson
- Department of Developmental Neurobiology, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
| | - P Lichter
- Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - A Gajjar
- Department of Oncology, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
| | - M Kool
- Division of Pediatric Neuro-Oncology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
| | - P A Northcott
- Department of Developmental Neurobiology, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
| | - S M Pfister
- Division of Pediatric Neuro-Oncology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
- Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany
| | - M F Roussel
- Department of Tumor Cell Biology, St Jude Children’s Research Hospital (SJCRH), Memphis, TN, USA
| |
Collapse
|
44
|
Baba S, Katsumata Y, Okamoto Y, Kawaguchi Y, Hanaoka M, Kawasumi H, Yamanaka H. Reliability of the SF-36 in Japanese patients with systemic lupus erythematosus and its associations with disease activity and damage: a two-consecutive year prospective study. Lupus 2017; 27:407-416. [DOI: 10.1177/0961203317725586] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
We aimed to validate the reliability of the Medical Outcomes Study Short Form-36 (SF-36) among Japanese patients with systemic lupus erythematosus (SLE). Japanese patients with SLE ( n = 233) completed the SF-36 and other related demographic questionnaires, and physicians simultaneously completed the SLE Disease Activity Index 2000 (SLEDAI-2K) and the Systemic Lupus International Collaborating Clinics Damage Index (SDI). Patients were prospectively followed for a repeat assessment the following year. The SF-36 subscales demonstrated acceptable internal consistency (Cronbach’s α of 0.85–0.89), and an overall good test–retest reliability (intraclass correlation coefficient >0.70). The average baseline SF-36 subscale/summary scores except for “bodily pain” were significantly lower than those of the Japanese general population ( p < 0.05). The SDI showed an inverse correlation with the SF-36 subscale/summary scores except for “vitality” and “mental component summary” at baseline, whereas the SLEDAI-2K did not. In the second year, “social functioning” and “mental component summary” of the SF-36 deteriorated among patients whose SDI or SLEDAI-2K score increased (effect sizes < −0.20). In conclusion, the SF-36 demonstrated acceptable reliability among Japanese patients with SLE. Health-related quality of life measured by the SF-36 was reduced in Japanese patients with SLE and associated with disease damage, rather than disease activity.
Collapse
Affiliation(s)
- S Baba
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - Y Katsumata
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - Y Okamoto
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - Y Kawaguchi
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - M Hanaoka
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - H Kawasumi
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - H Yamanaka
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| |
Collapse
|
45
|
Nozaki M, Kagami Y, Shibata T, Nakamura K, Ito Y, Nishimura Y, Kawaguchi Y, Saito Y, Nagata Y, Matsumoto Y, Akimoto T, Nishimura T, Uno T, Tsujino K, Kataoka M, Kodaira T, Shiraishi K, Inoue K, Isohashi F, Hiraoka M, Karasawa K, Izumi S, Sakurai H. EP-1156: A clinical trial on hypofractionated whole breast irradiation after breast-conserving surgery. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31592-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
46
|
Yamaguchi Y, Shirai Y, Ono J, Kawaguchi Y, Izuhara K, Kuwana M, Aihara M. 360 An elevated circulating level of periostin in patients with systemic sclerosis: Associations with functional impairment in various affected organs. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
47
|
Shizuma Y, Zaitsu T, Ueno M, Ohnuki M, Kawaguchi Y. Relationship between self-assessment and clinical evaluation of dental plaque and gingival condition in Japanese adolescents. Int J Dent Hyg 2017; 16:144-150. [DOI: 10.1111/idh.12281] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/22/2017] [Indexed: 11/29/2022]
Affiliation(s)
- Y Shizuma
- Department of Oral Health Promotion; Tokyo Medical and Dental University; Tokyo Japan
| | - T Zaitsu
- Department of Oral Health Promotion; Tokyo Medical and Dental University; Tokyo Japan
| | - M Ueno
- Department of Oral Health Promotion; Tokyo Medical and Dental University; Tokyo Japan
| | - M Ohnuki
- Department of Oral Health Promotion; Tokyo Medical and Dental University; Tokyo Japan
| | - Y Kawaguchi
- Department of Oral Health Promotion; Tokyo Medical and Dental University; Tokyo Japan
| |
Collapse
|
48
|
Kawaguchi Y, Nomura Y, Nagai M, Koike D, Sakuraoka Y, Ishida T, Ishizawa T, Kokudo N, Tanaka N. Liver transection using indocyanine green fluorescence imaging and hepatic vein clamping. Br J Surg 2017; 104:898-906. [PMID: 28239843 DOI: 10.1002/bjs.10499] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Revised: 12/02/2016] [Accepted: 01/04/2017] [Indexed: 12/15/2022]
Abstract
BACKGROUND Three-dimensional (3D) imaging has facilitated liver resection with excision of hepatic veins by estimating the liver volume of portal and hepatic venous territories. However, 3D imaging cannot be used for real-time navigation to determine the liver transection line. This study assessed the value of indocyanine green (ICG) fluorescence imaging with hepatic vein clamping for navigation during liver transection. METHODS Consecutive patients who underwent liver resection with excision of major hepatic veins between 2012 and 2013 were evaluated using ICG fluorescence imaging after clamping veins and injecting ICG. Regional fluorescence intensity (FI) values of non-veno-occlusive regions (FINon ), veno-occlusive regions (FIVO ) and ischaemic regions (FIIS ) were calculated using luminance analysing software. RESULTS Of the 21 patients, ten, four and seven underwent limited resection, monosegmentectomy/sectionectomy and hemihepatectomy respectively, with excision of major hepatic veins. Median veno-occlusive liver volume was 80 (range 30-458) ml. Fluorescence imaging visualized veno-occlusive regions as territories with lower FI compared with non-veno-occlusive regions, and ischaemic regions as territories with no fluorescence after intravenous ICG injection. Median FIIS /FINon was lower than median FIVO /FINon (0·22 versus 0·59; P = 0·002). There were no deaths in hospital or within 30 days, and only one major complication. CONCLUSION ICG fluorescence imaging with hepatic vein clamping visualized non-veno-occlusive, veno-occlusive and ischaemic regions. This technique may guide liver transection by intraoperative navigation, enhancing the safety and accuracy of liver resection.
Collapse
Affiliation(s)
- Y Kawaguchi
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.,Department of Surgery, Asahi General Hospital, Chiba, Japan
| | - Y Nomura
- Department of Surgery, Asahi General Hospital, Chiba, Japan
| | - M Nagai
- Department of Surgery, Asahi General Hospital, Chiba, Japan
| | - D Koike
- Department of Surgery, Asahi General Hospital, Chiba, Japan
| | - Y Sakuraoka
- Department of Surgery, Asahi General Hospital, Chiba, Japan
| | - T Ishida
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.,Department of Surgery, Asahi General Hospital, Chiba, Japan
| | - T Ishizawa
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - N Kokudo
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - N Tanaka
- Department of Surgery, Asahi General Hospital, Chiba, Japan
| |
Collapse
|
49
|
Morikawa H, Mano K, Horinaka H, Matsunaka T, Matsumoto Y, Ida T, Kawaguchi Y, Wada K, Kawada N. Development of non-invasive method for assessment of hepatic steatosis. Ultrasonics 2016; 72:195-200. [PMID: 27567038 DOI: 10.1016/j.ultras.2016.08.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Revised: 08/12/2016] [Accepted: 08/17/2016] [Indexed: 06/06/2023]
Abstract
Steatosis is a critical feature of liver disease and is considered to play a pivotal role in the progression of nonalcoholic fatty liver disease, as well as being a surrogate marker of metabolic syndrome. The purpose of this study was to develop a non-invasive diagnostic method for assessment of liver steatosis. It is well known that ultrasonic velocity depends on materials and temperature. For example, the ultrasonic velocity in water is 1530m/s at 37°C and 1534m/s at 39°C, while that in fat is 1412m/s at 37°C and 1402m/s at 39°C. On this basis, we thought that the percentage of fat in hepatic steatosis could be assessed by detecting changes of ultrasonic in the liver, caused by warming. In order to confirm the effectiveness of this method, we obtained the ultrasonic velocity changes of tissue phantom including lard oil and the liver of living rabbit by ultrasonic warming, and then succeeded in 2-D imaging of ultrasonic velocity changes of the phantom and the liver of living rabbit. We named this the ultrasonic velocity-change method. The experimental results show the possibility that hepatic steatosis could be characterized using our novel, non-invasive method.
Collapse
Affiliation(s)
- H Morikawa
- Department of Premier Preventive Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan.
| | - K Mano
- Department of Physics and Electronics, Graduate School of Engineering, Osaka Prefecture University, Sakai, Japan
| | - H Horinaka
- Department of Physics and Electronics, Graduate School of Engineering, Osaka Prefecture University, Sakai, Japan
| | - T Matsunaka
- Department of Physics and Electronics, Graduate School of Engineering, Osaka Prefecture University, Sakai, Japan
| | - Y Matsumoto
- Graduate School of Human Life Science, Osaka City University, Osaka, Japan
| | - T Ida
- Advantest Corporation, Tokyo, Japan
| | | | - K Wada
- Department of Physics and Electronics, Graduate School of Engineering, Osaka Prefecture University, Sakai, Japan
| | - N Kawada
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan
| |
Collapse
|
50
|
Kishi N, Imai Y, Kanayama N, Hirata T, Kawaguchi Y, Konishi K, Nishiyama K, Teshima T. Recurrence Patterns of Postoperative Radiation Therapy for Patients With Head and Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1610] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|